1-BOC-5-TBDMSO-吲哚-2-硼酸 | 335649-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-BOC-5-TBDMSO-吲哚-2-硼酸
• 中文别名: 2-硼-5-[[(1,1-二甲基乙基)二甲基硅酯]氧基]-1H-吲哚-1-羧酸-1-(1,1-二甲基乙酯)；1-Boc-5-(叔丁基二甲基硅烷)吲哚-2-硼酸；5-(叔丁基二甲基硅氧烷)-1H-吲哚-2-硼酸N-BOC；1-BOC-5-(叔丁基二甲基硅烷)吲哚-2-硼酸
• 英文名称: (1-(tert-butoxycarbonyl)-5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)boronic acid
• 英文别名: 5-(tert-Butyldimethylsilyloxy)-1H-indole-2-boronic acid, N-BOC protected；[5-[tert-butyl(dimethyl)silyl]oxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
• CAS: 335649-61-1
• 化学式: C₁₉H₃₀BNO₅Si
• 分子量: 391.347
• InChiKey: NXKIUYOUKLIWLP-UHFFFAOYSA-N

物化性质

• 熔点：
  104-106
• 沸点：
  486.7±55.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.49
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-5-TBDMSO-indole-2-boronic acid
Synonyms: 1-BOC-5-TBDMSO-2-indoleboronic acid; 1-(tert-Butoxycarbonyl)-5-(tert-butyldimethylsilyloxy)-
1H-indol-2-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
Store locked up
P405:

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-5-TBDMSO-indole-2-boronic acid
CAS number: 335649-61-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C19H30BNO5Si
Molecular weight: 391.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-BOC-5-TBDMSO-吲哚-2-硼酸 在 四(三苯基膦)钯 、 silica gel 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  作为高度选择性蛋白激酶抑制剂的结构复杂的八面体金属配合物

  摘要：

  生成具有专属目标特异性的合成化合物是分子识别的一项非凡挑战，需要新的设计策略，特别是对于大型同源蛋白质家族，例如拥有 500 多个成员的蛋白激酶。简单的有机分子通常达不到完成这项任务所需的复杂程度。在这里，我们展示了六种精心定制的、稳定的含金属化合物，其中独特且明确的分子几何结构具有类似天然产物的结构复杂性，围绕八面体钌 (II) 或铱 (III) 金属中心构建。六种报道的金属化合物中的每一种都对单个蛋白激酶显示出高选择性，即 GSK3α、PAK1、PIM1、DAPK1、MLCK 和 FLT4。虽然是传统的 ATP 竞争性抑制剂，这些化合物不寻常的球状形状和刚性特征的结合促进了高选择性蛋白激酶抑制剂的设计。八面体配位几何的独特结构特征允许与富含甘氨酸的环进行新的相互作用，这对结合效力和选择性有显着贡献。金属配位球与抑制特性之间的敏感相关性表明，在这种设计中，金属位于 ATP 结合口袋内的“

  DOI：

  10.1021/ja1112996
• 作为产物：
  描述：

  tert-butyl 5-(tert-butyldimethylsilyloxy)-1H-indole-1-carboxylate 在 硼酸三异丙酯 、 lithium diisopropyl amide 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正庚烷 、 乙基苯 为溶剂， 反应 1.08h， 以95%的产率得到1-BOC-5-TBDMSO-吲哚-2-硼酸
  参考文献：
  名称：

  作为高度选择性蛋白激酶抑制剂的结构复杂的八面体金属配合物

  摘要：

  生成具有专属目标特异性的合成化合物是分子识别的一项非凡挑战，需要新的设计策略，特别是对于大型同源蛋白质家族，例如拥有 500 多个成员的蛋白激酶。简单的有机分子通常达不到完成这项任务所需的复杂程度。在这里，我们展示了六种精心定制的、稳定的含金属化合物，其中独特且明确的分子几何结构具有类似天然产物的结构复杂性，围绕八面体钌 (II) 或铱 (III) 金属中心构建。六种报道的金属化合物中的每一种都对单个蛋白激酶显示出高选择性，即 GSK3α、PAK1、PIM1、DAPK1、MLCK 和 FLT4。虽然是传统的 ATP 竞争性抑制剂，这些化合物不寻常的球状形状和刚性特征的结合促进了高选择性蛋白激酶抑制剂的设计。八面体配位几何的独特结构特征允许与富含甘氨酸的环进行新的相互作用，这对结合效力和选择性有显着贡献。金属配位球与抑制特性之间的敏感相关性表明，在这种设计中，金属位于 ATP 结合口袋内的“

  DOI：

  10.1021/ja1112996

文献信息

• Novel organophosphorus derivatives of indazoles and use thereof as medicinal products
  申请人：Cherrier Marie-Pierre

  公开号：US20050137171A1

  公开（公告）日：2005-06-23

  The present invention relates in particular to novel chemical compounds, particularly to novel organophosphorus derivatives of indazoles, to the compositions containing them, and to the use thereof as medicinal products for treating cancers.

  本发明特别涉及新型化合物，特别是吲唑的新型有机磷衍生物，包含它们的组合物，以及将其用作治疗癌症的药物产品。
• [EN] THIENOPYRAZOLES<br/>[FR] THIENOPYRAZOLES
  申请人：AVENTIS PHARMA INC

  公开号：WO2005026175A1

  公开（公告）日：2005-03-24

  Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).

  噻唑并吡唑类化合物，其制备方法，包含这些化合物的药物组合物，以及它们在治疗可通过抑制蛋白激酶，特别是白细胞介素-2诱导酪氨酸激酶（ITK）而调节的疾病状态中的药用。
• [EN] RAPAMYCIN ANALOGS AS MTOR INHIBITORS<br/>[FR] ANALOGUES DE LA RAPAMYCINE UTILISÉS EN TANT QU'INHIBITEURS DE MTOR
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2018204416A1

  公开（公告）日：2018-11-08

  The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.

  本公开涉及一般式（I）的雷帕霉素类似物。这些化合物是mTOR的抑制剂，因此对于治疗癌症、免疫介导性疾病和与年龄相关的疾病是有用的。
• [EN] METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS<br/>[FR] MÉTHODES DE RETARDEMENT, DE PRÉVENTION ET DE TRAITEMENT DE LA RÉSISTANCE ACQUISE AUX INHIBITEURS DE RAS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2021257736A1

  公开（公告）日：2021-12-23

  The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

  本公开涉及使用双-立体异构体mTOR抑制剂与RAS抑制剂联合治疗疾病或病状（例如，癌症）的配方和方法。具体而言，在某些实施方式中，本公开包括用于诱导肿瘤细胞凋亡和/或用于延迟、预防或治疗对RAS抑制剂获得性耐药性的双-立体异构体mTOR抑制剂的配方和方法。
• [EN] SELECTIVE LIGANDS FOR TAU AGGREGATES<br/>[FR] LIGANDS SÉLECTIFS POUR AGRÉGATS TAU
  申请人：KARIN & STEN MORTSTEDT CBD SOLUTIONS AB

  公开号：WO2019197502A1

  公开（公告）日：2019-10-17

  The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate.The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy,or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

  该发明提供了化合物的结构式(I)：或其药学上可接受的盐、酯、酰胺或碳酸酯，或此类酯、酰胺或碳酸酯的盐。该发明还提供了化合物的结构式(I)的用途和包括化合物的结构式(I)的组合物，包括利用这些化合物检测tau沉积物的用途，以及将这些化合物和组合物用作诊断剂在诊断或监测疾病或障碍的进展，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症，或用于预防或治疗疾病或障碍，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症。